Information Provided By: 
Fly News Breaks for February 22, 2019
XNCR
Feb 22, 2019 | 07:20 EDT
Nomura Instinet analyst Christopher Marai last night downgraded Xencor to Reduce from Neutral and lowered his price target for the shares to $21 from $28. The analyst recommends reducing exposure to the shares after the company announced a partial clinical hold on the Phase 1 study of XmAb14045. The hold follows the report of two deaths that were possibly related to XmAb14045, Marai tells investors in a research note.
News For XNCR From the Last 2 Days
There are no results for your query XNCR
